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Abstract
Background: Medulloblastoma is the most common malignant brain tumor in children and remains a therapeutic
challenge due to its significant therapy-related morbidity. Polo-like kinase 1 (PLK1) is highly expressed in many
cancers and regulates critical steps in mitotic progression. Recent studies suggest that targeting PLK1 with small
molecule inhibitors is a promising approach to tumor therapy.
Methods: We examined the expression of PLK1 mRNA in medulloblastoma tumor samples using microarray
analysis. The impact of PLK1 on cell proliferation was evaluated by depleting expression with RNA interference
(RNAi) or by inhibiting function with the small molecule inhibitor BI 2536. Colony formation studies were
performed to examine the impact of BI 2536 on medulloblastoma cell radiosensitivity. In addition, the impact of
depleting PLK1 mRNA on tumor-initiating cells was evaluated using tumor sphere assays.
Results: Analysis of gene expression in two independent cohorts revealed that PLK1 mRNA is overexpressed in
some, but not all, medulloblastoma patient samples when compared to normal cerebellum. Inhibition of PLK1 by
RNAi significantly decreased medulloblastoma cell proliferation and clonogenic potential and increased cell
apoptosis. Similarly, a low nanomolar concentration of BI 2536, a small molecule inhibitor of PLK1, potently
inhibited cell growth, strongly suppressed the colony-forming ability, and increased cellular apoptosis of
medulloblastoma cells. Furthermore, BI 2536 pretreatment sensitized medulloblastoma cells to ionizing radiation.
Inhibition of PLK1 impaired tumor sphere formation of medulloblastoma cells and decreased the expression of SRY
(sex determining region Y)-box 2 (SOX2) mRNA in tumor spheres indicating a possible role in targeting tumor
inititiating cells.
Conclusions: Our data suggest that targeting PLK1 with small molecule inhibitors, in combination with radiation
therapy, is a novel strategy in the treatment of medulloblastoma that warrants further investigation.
Background
Medulloblastoma is the most common malignant brain
tumor in children. While therapy for standard-risk
patients has resulted in improved outcomes, high-risk
patients do poorly [1]. In addition, there remains signifi-
cant therapy-related morbidity, particularly in very
young patients. Recent genome wide analyses have iden-
tified multiple subgroups with differing outcomes [2,3].
These studies show the genetic heterogeneity of medul-
loblastoma and the need for new therapeutics based on
molecular signatures of these tumors. Although a variety
of signaling pathways (including Sonic Hedgehog, Wnt
and Notch) are known to be associated with medullo-
blastoma cell biology [4-6], so far new therapeutic inter-
ventions based on this knowledge have been slow to
develop. Thus, the mainstays of medulloblastoma ther-
apy continue to be surgery, radiation and cytotoxic che-
motherapy [7]. While these approaches have improved
the outcomes for low-risk patients, those with high-risk
disease still have suboptimal outcomes. Furthermore,
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cant long-term morbidity, especially in younger children
[8,9], and chemotherapy likewise has major side effects
[10]. Thus, there is a critical need for more effective
therapies to combat this disease.
To begin to address this need, we examined protein
kinase gene expression by transcriptional profiling and
found altered expression of multiple protein kinases in
medulloblastoma patient samples. Among these kinases is
aurora kinase A (AURKA), a target we have recently
shown to have therapeutic value in several brain tumors
[11,12]. Given that many protein kinases are key regulators
of proliferation, invasion, angiogenesis and metastasis, they
represent ideal targets for molecularly targeted cancer
therapy. Analysis of our previous data suggests that polo-
like kinase 1 (PLK1) is a potential therapeutic target in
medulloblastoma.
PLK1 is essential for mitosis. It promotes mitotic entry
by phosphorylating cyclin B1 and CDK1, and it initiates
mitotic exit by activating the Anaphase Promoting Com-
plex (APC) [13]. Overexpression of PLK1 promotes chro-
mosome instability and aneuploidy by overriding the G2-
M DNA damage and spindle checkpoints [13]. PLK1 is
overexpressed in a wide variety of cancers, and inhibition
of this kinase by shRNA or chemical inhibitors decreases
tumor growth both in vitro and in vivo [13-15]. Impor-
tantly, this inhibition preferentially kills cancer cells over
normal cells [16,17]. Phase I/II studies of inhibitors of
PLK1 in advanced solid tumors in adults have yielded
promising results [18,19]. The role of PLK1 in pediatric
tumors is less well characterized. Recent studies indicate
that it is a target in the treatment of rhabdomyosarcoma
and neuroblastoma [14,20,21].
In this study, our goal was to evaluate PLK1 as a poten-
tial therapeutic target in medulloblastoma. We determined
the expression of PLK1 mRNA in two independent
cohorts of medulloblastoma patients and investigated the
effect of PLK1 inhibition by RNA interference (RNAi) and
by the small molecule drug BI 2536 on medulloblastoma
cells in vitro.
Methods
Cell lines and primary patient samples
The Daoy and D283 medulloblastoma cell lines were
purchased from American Type Cell Culture (Rockville,
MD). The ONS-76 medulloblastoma cell line was kindly
provided by Dr. James T. Rutka (University of Toronto,
Canada). D425 and D458 cell lines were kindly provided
by Dr. Darell D. Bigner (Duke University Medical Cen-
ter, NC). Cell lines were cultured in DMEM (Gibco,
Carlsbad, CA) supplemented with 10% fetal bovine
serum (Atlanta Biologicals, Lawrenceville, GA).
Primary patient samples were obtained from Children’s
Hospital Colorado and were conducted in accordance
with local and federal human research protection guide-
lines and Institutional Review Board (IRB) regulations.
Informed consent was obtained for all specimens col-
lected. Normal brain tissue was collected from autopsy
and purchased from Ambion (Austin, TX), Stratagene
(Santa Clara, CA) and Clontech Laboratories, Inc. (Moun-
tain View, CA). Normal cerebellar samples in Figure 1 (A,
C, D) were obtained from nonmalignant brain biopsies at
the Children’s Hospital Colorado under IRB guidelines.
Normal cerebellar samples UPN 514 and UPN 605 are
from 4 year old and 5 year old patients, respectively.
Gene expression microarray analysis
Sixteen patient tumor samples comprising the first cohort
were evaluated for gene expression using Affymetrix U133
Plus 2.0 GeneChip microarrays as previously described
[22]. Briefly, samples were collected at the time of surgery
and snap-frozen in liquid nitrogen. Ribonucleic acid was
extracted from each sample using an RNeasy kit (Qiagen,
Valencia, CA) and hybridized to HG-U133 Plus 2.0 Gene-
Chips (Affymetrix, Santa Clara, CA) according to the man-
ufacturer’s instructions. Microarray data from the samples
was background-corrected and normalized using the
gcRMA algorithm. One probe set per gene, based on high-
est overall expression level across samples, was selected for
use in subsequent analyses. Differential expression of
genes was determined using a Student’s t-test [22].
All 120 tumor specimens in the second cohort were
obtained in accordance with the Research Ethics Board at
the Hospital for Sick Children (Toronto, Canada), as
described, and the N. N. Burdenko Neurosurgical Institute
(Moscow, Russia) [2]. Gene expression array data were
generated and analyzed as described [2].
Transfection of RNAi vectors
Three siRNAs targeting PLK1 mRNA, siPLK1-A (s448),
siPLK1-B (s449) and siPLK1-C (s450), and a non-target-
ing siRNA were transfected into medulloblastoma cell
lines using the siPORT NeoFX Transfection Agent
(Ambion). A final concentration of 5 nM of siRNA was
transfected into the medulloblastoma cell lines. The
manufacturer’s suggested protocol for a reverse transfec-
tion was used with the siRNA. Of the three siRNAs tar-
geting PLK1, siPLK1-A was used in further experiments
due to its higher efficacy in inhibiting PLK1 (Additional
file 1: Figure S1 [B, C, D]).
Two shRNA vectors targeting PLK1 mRNA (1073:
CCGGCGAGCTGCTTAATGACGAGTTCTCGAGAA
CTCGTCATTAAGCAGCTCGTTTTTG and 1325: CCG
GCCCGAGGTGCTGAGCAAGAAACTCGAGTTTCT
TGCTCAGCACCTCGGGTTTTTG) and a non-targeting
shRNA (shNTC) were purchas e df r o mt h eF u n c t i o n a l
Genomics Facility at the University of Colorado, Boulder,
and transfected into medulloblastoma cell lines using the
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Carlsbad, CA). The shPLK1 1325 vector was used in
further experiments due to its greater inhibition of PLK1
(Additional file 1: Figure S1 [A, D]). One microgram of
shRNA for a 6-well plate was transfected into the medul-
loblastoma cell lines. The ratio used for the forward trans-
fections was 1 microgram of shRNA DNA: 2 μlo f
Lipofectamine 2000 Transfection Reagent.
Quantitative real-time polymerase chain reaction
Ribonucleic acid was isolated 48 hours after transfection
using a Qiagen RNeasy kit (Valencia, CA). TaqMan gene
expression primers and probes for PLK1 (Hs00153
444_m1), SOX2 (Hs01053049_s1), NES (Hs00707120_s1),
Nanog (Hs002387400_g1), c-Myc (Hs01570247_m1), and
GAPDH (Hs99999905_m1) were purchased from Applied
Biosystems (Carlsbad, CA). Assays were performed in tri-
plicate according to the manufacturer’s recommendations.
GAPDH was used as an endogenous control and the gene
expression relative quantity was calculated using the ΔΔCt
method. Gene expression assays were performed on an
ABI StepOnePlus Real-Time PCR system.
Small molecule inhibitors of PLK1
The small molecule PLK1 inhibitors BI 2536 and BI
6727 were purchased from Axon Medchem (Gronin-
berg, Netherlands). The drugs were reconstituted in
dimethyl sulfoxide (DMSO) and aliquots were stored in
Figure 1 Overexpression of PLK1 in medulloblastoma.( A) PLK1 mRNA levels by microarray in 16 primary medulloblastoma (Med) patient
samples compared to three normal cerebellum (Normal CB) samples. Error bars represent standard error of the mean (SEM). (B) Microarray
expression of PLK1 mRNA in 120 patients with medulloblastoma (Med). A significant overexpression is seen in medulloblastoma when compared
to adult cerebellum (adult CB). There is no significant difference when medulloblastoma samples are divided into four subgroups (WNT, SHH,
Group C and Group D). Error bars represent SEM. (C) Significantly higher PLK1 mRNA expression is seen in medulloblastoma cell lines compared
to normal adult cerebellum (Stratagene and Clontech) and pediatric cerebellum (UPN 514 and UPN 605) by qRT-PCR. Error bars represent SEM.
(D) Western blot of PLK1 protein expression in normal cerebellum and medulloblastoma cell lines
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Page 3 of 13a desiccator at -20°C. An equivalent amount of DMSO
for the highest concentration of drug was used for each
experiment as a vehicle control.
Cell proliferation and apoptosis assays
Cell proliferation was determined by MTS [3-(4, 5-
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-
sulfophenyl)-2H-tetrazolium] assay using CellTiter 96
AQueous One Solution (Promega, Madison, WI). Seventy-
two hours after transfection with siRNA, 20 μlo fM T S
reagent was added to the wells already containing 100 μl
of media. For drug treatment, cells were plated for 24
hours before adding BI 2536 or BI 6727. Then 72 hours
after the addition of the drug, 30 μl of MTS reagent were
added to the wells to make a final volume of 180 μl. Plates
were read using a BioTek Synergy 2 plate reader
(Winooski, VT) every hour for 4 hours after the addition
of the MTS reagent. Experiments were done in triplicate
and background absorbance was subtracted from all wells
before analysis.
For the colony formation assay, cells were transfected
with shRNA for 48 hours and then plated at 500 cells per
well of a 6-well plate in triplicate. For drug treatment, 500
cells per well of a 6-well plate were plated in triplicate 24
hours before addition of BI 2536. Wells were then treated
with drug for 24 hours and then allowed to grow in nor-
mal culture medium. After seven days of growth, the med-
ium was aspirated, the wells were washed with PBS, and
the colonies were stained with 0.5% crystal violet/25%
methanol solution. The number of colonies per well was
counted using a dissecting microscope with a threshold of
50 cells necessary to constitute a colony.
Apoptosis was assessed 72 hours after siRNA transfec-
tion or after 24 hours of BI 2536 treatment followed by 24
hours in normal culture medium. Cells were counted fol-
lowing staining with Guava ViaCount reagent (Millipore,
Billerica, MA) and the amount of apoptosis determined
using Guava Nexin reagent (Millipore). Samples were run
on a Guava EasyCyte Plus flow cytometer (Millipore).
Western blotting
Protein lysates were obtained from samples using RIPA
buffer (Thermo Scientific, Rockford, IL) with protease
inhibitors added. Western blotting was performed per
standard methods. Antibodies for PLK1 (#4535) and
Actin (MAB1501) were purchased from Cell Signaling
Technology (Danvers, MA) and Millipore, respectively.
Secondary antibodies conjugated to horseradish-peroxi-
dase were used in conjunction with a chemiluminescent
reagent to visualize protein bands.
Combination of BI 2536 and ionizing radiation
Five hundred cells per well of a 6-well plate were plated
in triplicate for 24 hours before addition of BI 2536.
Cells were exposed to drug for 24 hours, and then drug-
containing medium was aspirated and normal culture
medium was added. Cells were then immediately irra-
diated. After eight days of additional growth, wells were
stained with crystal violet solution and colonies were
counted as described above. Survival curves were gener-
ated after normalizing for the amount of BI 2536-
induced death. Non-linear regressions were calculated
for each line. The radiation dose intersecting the non-
linear regression for a 10% (SF0.1) and 50% (SF0.5) sur-
viving fraction was calculated for each drug dose. The
sensitizer enhancement ratio (SER) was then calculated
as follows:
SER =
SFxfor DMSO
SFxfor × nM BI 2536
Tumor sphere formation
Daoy medulloblastoma cells were either transfected with
shRNA or treated with 5 nM BI 2536. Forty-eight hours
after transfection or drug treatment, cells were trypsi-
nized and counted. Ten thousand cells were seeded in a
low-attachment 6-well plate in neurobasal medium
(Gibco) supplemented with fibroblast growth factor,
2 0n g / m L( S i g m a - A l d r i c h ,S t .L o u i s ,M O ) ,B - 2 7( G i b c o ) ,
epidermal growth factor, 20 ng/mL (Sigma-Aldrich), and
L-glutamine (Gibco). Tumor spheres were allowed to
grow for 7 days. After 7 days, pictures were taken with an
inverted microscope and subsequently the tumor spheres
were either processed for RNA isolation, or dissociated
and passaged to form secondary tumor spheres. The pri-
mary tumor spheres were dissociated with Accutase
(Millipore, Scr005) and resuspended in PBS. Ten thou-
sand cells from the primary tumor spheres were seeded
on a low attachment plate. The formation of secondary
tumor spheres was seen 4 days after seeding. The dia-
meter of the tumor spheres was measured using QCap-
ture Pro software from saved images captured at 4×
maginification.
Statistical analysis
Statistical significance was determined using a Student’s
t-test. Error bars represent the standard error of the
mean (n ≥ 3). GraphPad Prism 5 was used to calculate
IC50 values and to compute the nonlinear regression
equations.
Results
Plk1 is overexpressed in medulloblastoma
We initially hypothesized that kinases involved in cell
cycle regulation would be likely candidates as novel
therapeutic targets in medulloblastoma. To begin to
address this question, we first examined expression of
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loblastoma patients we had previously studied [23]. We
found that expression of PLK1 mRNA was altered in
most, but not all, of our patient samples when com-
pared to normal cerebellum (Figure 1A). There was no
clear correlation between the high PLK1-expressing
samples and age, gender or outcomes. Recent genomic
analysis defined four major subgroups of medulloblas-
toma. The 4 major subgroups are Sonic Hedgehog sig-
naling (SHH), Wnt signaling (WNT), Group C and
G r o u pD .G r o u pCa n dDt e n dt ob em o r ea g g r e s s i v e
than the SHH or WNT signaling groups [2]. To further
elucidate whether there was a correlation within the
subgroups of medulloblastoma, we examined expression
of PLK1 mRNA in a cohort of 120 recently described
medulloblastoma samples [2]. Medulloblastoma samples
expressed significantly higher PLK1 mRNA compared to
adult cerebellum (p < 0.00003), but PLK1 mRNA
expression was not significantly higher when compared
to fetal cerebellum (Figure 1B). When examined at the
genomic subgroup level, there was no difference in
PLK1 mRNA expression among the four major genomic
s u b g r o u p s( F i g u r e1 B ) .T h e s ed a t ai n d i c a t et h a tPLK1
may be associated with the oncogenic process in general
and is not specific to a particular molecular subgroup of
medulloblastoma. We next evaluated expression of
PLK1 mRNA in a panel of well-characterized medullo-
blastoma cell lines. Consistent with our patient tissue
data, all medulloblastoma cell lines tested expressed
PLK1 mRNA at significantly higher levels (p < 0.01)
compared to normal pediatric and adult cerebellum
(Figure 1C). We next examined PLK1 protein expression
in normal pediatric and adult cerebellum as well as a
panel of medulloblastoma cell lines. As seen in Figure
1D, pediatric cerebellum (UPN 514 and 605) and adult
cerebellum have minimal PLK1 protein expression while
all the medulloblastoma cell lines have increased but
varied levels of PLK1 protein.
Inhibition of PLK1 suppresses medulloblastoma cell
growth and colony forming ability
To examine whether PLK1 was functionally important
for medulloblastoma tumorigenesis, we initially
decreased expression of PLK1 mRNA by siRNA and
shRNA. Knockdown of PLK1 was verified by qRT-PCR
and by western blot analysis (Additional file 1: Figure S1).
For further experiments siPLK1-A and shPLK1 1325
were used due to their greater inhibition of PLK1. Using
the MTS assay, we found a significant decrease in cell
proliferation of two different medulloblastoma cell lines,
Daoy and ONS-76, transfected with PLK1 siRNA com-
pared to control siRNA (Figure 2A). We chose to evalu-
ate Daoy and ONS-76 cells because they are well
characterized, have high levels of PLK1 mRNA and we
have previous experience transfecting them [24]. Impor-
tantly, Daoy is p53 mutant and ONS-76 has wild type
p53 so any potential effect of p53 status on PLK1 inhibi-
tion can be interesting. To evaluate a longer-term impact,
we then performed colony formation assays on cells
transfected with control or PLK1 shRNA. Once again,
inhibition of PLK1 mRNA by RNAi significantly
decreased medulloblastoma cell growth as measured by
their ability to form colonies (Figure 2B). Interestingly, in
ONS-76 cells there was a much more marked inhibition
in the colony formation capability compared to measur-
ing just cell proliferation (89% inhibition versus 20% inhi-
bition, respectively). These data may reflect the impact of
PLK1 on tumor cell self-renewal compared to just
mitosis.
PLK1 inhibition induces apoptosis in medulloblastoma
cells
Inhibition of PLK1 induces the spindle checkpoint with
subsequent induction of cell death [25]. To evaluate
whether decreased expression of PLK1 mRNA resulted in
apoptosis in medulloblastoma, we analyzed Annexin V
expression on medulloblastoma cells by flow cytometry.
A ss h o w ni nt h er e p r e s e n t a t i v ep l o t si nF i g u r e3 A ,
siPLK1-A, but not non-silencing control (siRNA N.C.),
potently induced apoptosis as detected by increased
Annexin V expression in both Daoy and ONS-76 medullo-
blastoma cell lines. The difference in apoptosis between
the non-silencing siRNA control and siPLK1-A was statis-
tically significant in multiple independent replicates (Fig-
ure 3B). These data suggest that PLK1 could indeed be a
promising therapeutic target for medulloblastoma.
Small molecule inhibitor BI 2536 is a potent inhibitor of
medulloblastoma cell growth by increased apoptosis
Recently, several inhibitors of PLK1 have been described
[13]. Among these is the dihydropteridinone derivative BI
2536 (Boehringer Ingelheim, Ingelheim, Germany). We
determined whether BI 2536, like PLK1 siRNA, decreases
proliferation of medulloblastoma cells. Daoy and ONS-76
cells were treated with varying concentrations of BI 2536
and cell proliferation was evaluated by the MTS assay. BI
2536 potently inhibited cell growth with an IC50 of 5 nM
for Daoy and 7.5 nM for ONS-76 cells after 72 hours of
treatment (Figure 4A). To further examine the effects of
BI 2536 on medulloblastoma cells, we performed colony
formation assays. We found that BI 2536 strongly sup-
pressed the ability of medulloblastoma cells to form colo-
nies. Representative colonies are shown in Figure 4B.
To determine whether this decreased proliferation was
due to apoptosis, we evaluated Annexin V expression on
the surface of BI 2536-treated medulloblastoma cells by
flow cytometry. Representative plots are shown in Figure
4C for Daoy and in Additional file 2: Figure S2A for
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AAD) negative cells, indicative of early apoptosis, were
present at low levels in DMSO control-treated cells. This
population increased with escalating doses of BI 2536. In
addition, the Annexin V positive–7-AAD positive popu-
lation was significantly enhanced in BI 2536 cells, indicat-
ing increased late apoptosis. The total percentage of
apoptosis is quantified in Figure 4D and in Additional file
2: Figure S2B for Daoy and ONS-76, respectively.
BI 2536 enhances radiation sensitivity of
medulloblastoma cells
BI 2536 is a promising agent for combination therapy in
medulloblastoma. To investigate whether BI 2536
enhances cellular sensitivity to ionizing radiation,
medulloblastoma cells were exposed to BI 2536 for 24
hours before irradiation and the effects evaluated using
the colony formation assay. The results show that the
survival fractions (SF) at different radiation dosages
Figure 2 Decrease in medulloblastoma cell growth and colony forming ability following PLK1 mRNA inhibition by RNAi.( A) A significant
decrease in relative cell number was seen in both Daoy and ONS-76 cell lines by MTS assay 72 hours following siRNA-mediated inhibition of PLK1
mRNA. Error bars represent SEM. (B) Long-term decrease in growth as seen through a colony formation assay following knockdown of PLK1 mRNA with
shRNA in Daoy and ONS-76 cell lines. Representative pictures of wells for each cell line are below the quantifying graphs. Error bars represent SEM
Harris et al. BMC Cancer 2012, 12:80
http://www.biomedcentral.com/1471-2407/12/80
Page 6 of 13were reduced in Daoy (Figure 5A) and ONS-76 (Figure
5D) cells after they were exposed to BI 2536. Survival
fractions of BI 2536-pretreated cells after 2 Gray irradia-
tion were significantly lower than those of untreated
cells (Figure 5 [B, E]). Nonlinear regressions were fit to
the curves to assist in calculating the sensitizer enhance-
ment ratio (SER) (Additional file 3: Figure S3). The sen-
sitizer enhancement ratios were 1.8 for Daoy at 10% cell
survival (SF0.1) and 1.9 at 50% cell survival (SF0.5) with
5 nM BI 2536 pre-treatment (Figure 5C). For ONS-76
Figure 3 Increased apoptosis following PLK1 mRNA inhibition by RNAi.( A) Medulloblastoma cell lines Daoy and ONS-76 were transfected
with either a non-silencing siRNA (siRNA N.C.) or a siRNA targeting PLK1 (siPLK1-A) for 72 hours and stained with Guava Nexin reagent.
Representative flow cytometry plots for the two cell lines are shown. Percentages of cells in the bottom left quadrant are live while cells to the
right of the vertical line are apoptotic or dead. (B) Quantifying bar graphs showing a significant increase in the percentage of apoptotic/dead
cells following PLK1 mRNA knockdown with siRNA in both Daoy and ONS-76 cell lines. Error bars represent SEM
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Page 7 of 13Figure 4 Inhibition of PLK1 with BI 2536 decreases cell growth and increases apoptosis.( A) Decrease in the relative cell number of two
medulloblastoma cell lines, Daoy and ONS-76, through a wide range of BI 2536 concentrations treated for 72 hours. Error bars represent SEM.
(B) Quantifying bar graph showing a significant decrease in the ability of two medulloblastoma cell lines in forming colonies following 24 hour
treatment with BI 2536. Error bars represent SEM. Shown below are representative pictures of the wells from the colony formation assay. (C)
Representative flow cytometry plots for Daoy cells stained with Guava Nexin reagent following 24 hours of treatment with BI 2536. Percentages
of cells in the bottom left quadrant are live while cells to the right of the vertical line are apoptotic or dead. (D) Bar graph quantifying the
percentage of apoptotic/dead cells following Guava Nexin reagent staining. Error bars represent SEM
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and 6.4 for SF0.1 and SF0.5, respectively (Figure 5F).
Thus, the radiation survival curves obtained by the col-
ony formation assay showed that BI 2536 pretreatment
sensitized human medulloblastoma cells to ionizing
radiation.
Inhibition of PLK1 mRNA decreases tumor sphere
formation and decreases SOX2 mRNA expression
We next evaluated the hypothesis that inhibition of PLK1
mRNA impairs tumor initiating cells in medulloblastoma.
We cultured Daoy cells in a non-adherent culture system
in the presence of serum-free stem cell media (neurobasal
with EGF, FGF and B27). Under these conditions Daoy
cells form robust tumor spheres (Figure 6A). These tumor
spheres upregulate mRNA expression of many stem and
progenitor markers including S O X 2 ,N a n o g ,N E Sand c-
Myc as shown in Additional file 4: Figure S4A and as pre-
viously described for CD133 and CD44 [26]. Daoy cells
were transfected with non-targeting shRNA (shNTC) or
with shPLK1 plasmids. Forty-eight hours post-transfec-
tion, cells were transferred to the non-adherent culture
system and tumor sphere growth was monitored. By seven
days post-transfection, untreated and shNTC-transfected
cells formed tumor spheres with a mean diameter of 300-
360 μm. In contrast, shPLK1-transfected cells formed sig-
nificantly smaller (176 μm) spheres (Figure 6A). We next
measured a panel of stem/progenitor cell markers by qRT-
PCR (Additional file 4: Figure S4B). We found that RNAi-
mediated inhibition of PLK1 mRNA in tumor spheres sig-
nificantly decreased SOX2 mRNA expression compared to
control transfected cells (Figure 6B) with no significant
change in NES, Nanog,a n dc-Myc mRNA expression
(Additional file 4: Figure S4B). Interestingly, inhibition of
PLK1 mRNA in standard adherent cultures did not signifi-
cantly alter SOX2 mRNA expression (Figure 6B). The
mechanism by which PLK1 acts upon SOX2 is unclear
and requires further detailed study.
Figure 5 Pretreatment with BI 2536 enhances radiation sensitivity in medulloblastoma cell lines.( A) Line graph plotting the surviving
fraction of Daoy cells given different radiation doses following 24 hours of treatment with BI 2536 or the vehicle control DMSO. Blue line and
symbols represent DMSO treated cells. Green line and symbols represent cells treated with 3 nM BI 2536. Red line and symbols represent cells
treated with 5 nM BI 2536. (B) Bar graph showing the quantification of the surviving fraction following 2 Gray (Gy) irradiation. (C) Sensitizer
enhancement ratio (SER) for Daoy cells. Blue bars are calculated using a survival fraction of 10% (SF0.1) and green bars are calculated using a
survival fraction of 50% (SF0.5). (D) Line graph plotting the surviving fraction of ONS-76 cells. Blue line and symbols represent DMSO treated
cells. Green line and symbols represent cells treated with 3.75 nM BI 2536. Red line and symbols represent cells treated with 7.5 nM BI 2536. (E)
Bar graph quantifying the surviving fraction at the 2 Gray (Gy) level of irradiation for ONS-76 cells. Error bars represent SEM. (F) Bar graph
depicting the sensitizer enhancement ratio in ONS-76 cells. Blue bars are calculated using a survival fraction of 10% (SF0.1) and green bars are
calculated using a survival fraction of 50% (SF0.5)
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sphere formation in the Daoy cell line. BI 2536 decreased
the size of the tumor spheres (479.2 μmf o rt h eD M S O
control treated vs. 142 μm for the 5 nM BI 2536 treated)
consistent with the RNAi experiments (Additional file 5:
Figure S5A). Interestingly, if we dissociate these primary
tumor spheres and reseed them, the diameter of the seri-
ally passaged secondary tumor spheres is also
Figure 6 Reduction in both tumor sphere size and SOX2 expression following PLK1 mRNA inhibition by RNAi.( A) Bar graph quantifies
the average tumor sphere diameter for the three different conditions: Daoy undergoing no treatment, transfected with non-targeting shRNA
(shNTC), or shRNA targeting PLK1 (shPLK1 1325). Error bars represent SEM. Shown below the bar graph are the representative pictures of Daoy
primary tumor spheres. The diameter of the tumor spheres was measured using QCapture Pro software from saved images. Magnification 4×. (B)
Bar graph quantifying the levels of SOX2 mRNA expression in Daoy cells following shRNA transfection. Red bars represent mRNA levels in cells
grown in standard adherent monolayer conditions. Blue bars depict mRNA levels for cells grown in the non-adherent tumor sphere conditions.
Error bars represent SEM
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treated vs. 171.4 μm for the cells previously treated with
5 nM BI 2536; Additional file 5: Figure S5B). We con-
clude therefore that PLK1 plays a key role in regulating
stem-like characteristics of tumor cells.
Discussion
Therapy-associated side effects in medulloblastoma have
led to a concentrated search for novel therapeutic tar-
gets, particularly targets for which inhibition has radio-
sensitizing potential and minimal toxicities. Recent
genomic studies have begun to unravel the molecular
mechanisms involved in medulloblastoma, but have not
yet resulted in novel therapeutic agents [2,3,27]. Analysis
of protein kinase gene expression revealed that expres-
sion of multiple protein kinases was altered in medullo-
blastoma, including several components of the mitotic
machinery such as aurora kinase A and PLK1 [23]. Per-
turbing mitosis by disrupting the proper formation of
mitotic spindles required for chromosome alignment
and segregation has been shown to preferentially kill
cancer cells [28].
It is well established that PLK1 plays an important
role in cell cycle regulation by functioning in centro-
some maturation, spindle formation, mitotic entry and
cytokinesis. Elevated PLK1 levels have been found in
many adult cancers, including breast and colorectal can-
cer, and in pediatric cancers, including neuroblastoma
and rhabdomyosarcoma [20,21,29]. While PLK1 mRNA
expression is upregulated in medulloblastoma, the sig-
nificance of PLK1 in the pathogenesis and management
of this pediatric brain tumor is not well understood.
In this study we demonstrate that PLK1 mRNA is over-
expressed in two independent medulloblastoma cohorts
when compared to normal cerebellum. Of note, fetal tis-
sues expressed very high levels of PLK1 mRNA compared
to adult brain tissues. This may reflect the critical role
PLK1 in regulating mitosis. Indeed PLK1 is essential for
progression into mitosis during embryonic development.
PLK1-deficient cells displayed mitotic infidelity resulting
in mitotic arrest and finally death during zebrafish
embryogenesis [30]. Furthermore, PLK1 homozygous
null mice were found to be embryonic lethal and the inci-
dence of tumors in PLK1 heterozygotes was three-fold
greater than that in their wild-type counterparts, again
emphasizing the importance of PLK1 in normal embryo-
genesis and development [31]. Interestingly, not all
tumor samples overexpressed PLK1 mRNA, further
emphasizing the molecular heterogeneity of this tumor.
Decreasing the expression of PLK1 mRNA by RNAi
clearly resulted in growth suppression and induction of
apoptosis in medulloblastoma cells. Furthermore, we
show that inhibition of PLK1 by a small molecule inhibi-
tor, BI 2536, results in a significant reduction in the
proliferation of medulloblastoma cells both in short-term
and long-term assays. Importantly, IC50 values were in
the low nanomolar range, which is in line with achievable
therapeutic plasma concentrations demonstrated in clini-
cal phase I/II trials of BI 2536 [18]. Treatment with 5 nM
BI 2536 in Daoy and 7.5 nM in ONS-76 medulloblatoma
cells induced apoptosis, which is consistent with results
found in other cancer cells [20].
BI 2536 (Boehringer Ingelheim, Ingelheim, Germany) is
a first-in-class PLK1 inhibitor. Not only is it an ATP-
competitive kinase inhibitor that inhibits the enzymatic
activity of PLK1, it also shows over 1,000-fold selectivity
for PLK1 against a large panel of other tyrosine and ser-
ine/threonine kinases [18,29]. In dose-escalation Phase I
trials, BI 2536 was well tolerated [18]. Several Phase II
studies are underway or have recently been completed
for BI 2536 [29]. In addition to BI 2536, there are several
other inhibitors of PLK1 in development and undergoing
clinical testing. These include BI 6727 (Boehringer Ingel-
heim, Ingelheim, Germany), GSK461364 (GlaxoSmithK-
line, Middlesex, UK) and HMN-214 (Nippon Shinyaku
Co. Ltd, Kyoto, Japan). However, there are currently no
clinical studies of PLK1 inhibitors in any pediatric can-
cers. Our data and those of Ackermann, et al., and Hu, et
al., strongly argue for development of such studies in
pediatric solid tumors [20,21]. In particular our data
show that PLK1 is a target in all subgroups of medullo-
blastomas making it ideal for clinical trials.
Radiation is a key component of medulloblastoma
therapy. Unfortunately, it results in significant morbid-
ity, particularly in very young patients [9]. Thus, agents
that radiosensitize medulloblastoma cells would be of
great utility. Here we show that low nanomolar concen-
trations of BI 2536 strongly decreased the surviving frac-
tion of tumor cells in response to radiation and
increased the sensitizer enhancement ratios. These
results indicate that BI 2536 can effectively enhance
medulloblastoma cell radiosensitivity in vitro.T h e s e
data are in accordance with previous studies showing
increased radiosensitivity in malignant cells depleted of
PLK1 mRNA by RNAi [32].
It has been hypothesized that medulloblastoma tumors
contain stem cell-like tumor-initiating cells that are
more resistant to therapy [33,34]. Here we found that
inhibition of PLK1 expression significantly decreased the
tumor sphere size and decreased the expression of the
stem cell marker SOX2. Interestingly, the decrease in
stem cell markers was more pronounced in tumor
spheres than in monolayer cells cultured in normal
adherent conditions. Thus, there is a clear role for PLK1
in tumor-initiating cells, a finding hinted at in recent
data from neuroblastoma [14]. It will be important to
elucidate in detail the specific mechanisms by which
PLK1 mediates tumor-initiating cell growth.
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exploring the role of PLK1 inhibition in medulloblas-
toma. Regarding the PLK1 inhibitors, a second PLK1
inhibitor, BI 6727, has been used in several studies [35].
BI 6727 is similar to BI 2536 in its in vitro activity in
Daoy and ONS-76 medulloblastoma cell lines (Addi-
tional file 6: Figure S6). In in vivo studies, BI 6727
shows better toxicity and pharmacokinetic profile com-
pared to BI 2536. The next step will be to perform care-
fully constructed animal studies. We plan to perform
orthotopic cerebellar xenograft in vivo studies with BI
6727. We will especially take in to consideration dosing
schedules and pharmacodynamic marker evaluation.
These data will assist in developing future clinical trials.
Conclusion
Our data, together with previous studies, strongly sug-
gest that targeting PLK1 with small molecule inhibitors
in combination with radiation therapy is both a novel
strategy in the treatment of medulloblastoma and one
that warrants further study.
Additional material
Additional file 1: Figure S1. RNAi transfection decreases PLK1 mRNA
and protein levels in medulloblastoma cell lines. Quantifying bar graphs
depicting significant decreases in PLK1 mRNA levels in Daoy
medulloblastoma cell line transfected: (A) with either a non-targeting
shRNA (shNTC) or two different shRNAs targeting PLK1 (shPLK1 1073 and
shPLK1 1325), (B) with either a scrambled siRNA (siRNA N.C.) or three
different siRNAs targeting PLK1 (siPLK1-A, siPLK1-B, and siPLK1-C). Error
bars represent SEM. (C) ONS-76 cells show a significant decrease in PLK1
mRNA expression following transfection with siPLK1-A. Error bars
represent SEM. (B) Western blot analysis confirms that RNAi-mediated
knockdown of PLK1 decreases the level of PLK1 protein in both Daoy
and ONS-76 cells.
Additional file 2: Figure S2. Inhibition of PLK1 by the small molecule
inhibitor BI 2536 increases apoptosis in ONS-76 cells. (A) Representative
plots for ONS-76 cells stained with Guava Nexin reagent following 24
hours of treatment with BI 2536 or an equivalent amount of the drug’s
vehicle DMSO. Percentages of cells in the bottom left quadrant are live
while cells to the right of the vertical line are apoptotic or dead. (B) The
bar graph quantifies the average percentage of apoptotic/dead cells.
Error bars represent SEM.
Additional file 3: Figure S3. Nonlinear regression lines for
medulloblastoma cells treated with BI 2536 followed by radiation. (A)
Daoy cells: the blue line is for DMSO treated cells, the green line for cells
treated with 3 nM BI 2536, and the red line for cells treated with 5 nM BI
2536. (B) ONS-76 cells: the blue line is for DMSO treated cells, the green
line is for cells treated with 3.75 nM BI 2536, and the red line is for cells
treated with 7.5 nM BI 2536. The R
2 values for each line are listed below
their respective graphs.
Additional file 4: Figure S4. Quantitative real-time PCR measure of the
mRNA expression of stem/progenitor markers in Daoy cells. (A) Daoy cells
were cultured under standard conditions or serum-free conditions. Stem/
progenitor cell markers increase when cells are grown under serum-free
tumor sphere conditions compared to standard serum containing adherent
monolayer conditions. (B) Knockdown of PLK1 mRNA with shPLK1 1325
decreases SOX2 mRNA in Daoy cells grown as tumor spheres. There was no
significant change in Nanog, NES,o rc-Myc mRNA.
Additional file 5: Figure S5. BI 2536 decreases Daoy tumor sphere
diameter. Daoy cells treated for 48 hours with 5 nM BI 2536 show decreased
tumor sphere diameter in both (A) primary tumor spheres and (B) secondary
tumor spheres. The diameter of the tumor spheres was measured using
QCapture Pro software from saved images. Magnification 4×.
Additional file 6: Figure S6. Second generation PLK1 inhibitor BI 6727
induces growth arrest of medulloblastoma similar to BI 2536. Decrease in
the relative cell number of two medulloblastoma cell lines, (A) Daoy and
(B) ONS-76, treated for 72 hours with either BI 2536 (blue line and
symbols) or BI 6727 (green line and symbols) as measured by MTS assay.
Error bars represent SEM.
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